External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

ImmuneOnco Biopharmaceuticals (Shanghai) / Equity Bottom-Up

<ul><li>Successful overseas licensing of PD-L1xVEGF bsAb and anti-CTLA4 mAb.</li><li>ImmuneOnco reached an agreement with SynBioTx (a wholly - owned subsidiary of Instil Bio (TIL US)), pursuant to which Instil will inlicense the ex-China rights to ImmueOnco’s proprietary PD-L1xVEGF bispecific molecule IMM2510, as well as its next-generation anti-CTLA-4 antibody (ADCC+) IMM27M.</li><li>ImmuneOnco will receive an upfront payment and potential near-term payments of up to US$50mn as well as potential additional development, regulatory, and commercial milestones payments exceeding US$2.1bn, plus single digit to low double-digit percentage royalties on global ex-China net sales.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Successful overseas licensing of PD-L1xVEGF bsAb and anti-CTLA4 mAb.ImmuneOnco reached an agreement with SynBioTx (a wholly - owned subsidiary of Instil Bio (TIL US)), pursuant to which Instil will inlicense the ex-China rights to ImmueOnco’s proprietary PD-L1xVEGF bispecific molecule IMM2510, as well as its next-generation anti-CTLA-4 antibody (ADCC+) IMM27M.ImmuneOnco will receive an upfront payment and potential near-term payments of up to US$50mn as well as potential additional development, regulatory, and commercial milestones payments exceeding US$2.1bn, plus single digit to low double-digit percentage royalties on global ex-China net sales.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

ImmuneOnco (1541 HK) - Achieved Significant Overseas Licensing Partnership

China

ImmuneOnco Biopharmaceuticals (Shanghai) (IOB HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ImmuneOnco (1541 HK) - Achieved Significant Overseas Licensing Partnership

Successful overseas licensing of PD-L1xVEGF bsAb and anti-CTLA4 mAb. ImmuneOnco reached an agreement with SynBioTx (a wholly - owned subsidiary of...

CMB International